Arcutis Biotherapeutics Inc (ARQT) Stock Price, Quote & News

Company Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 418 5006

Website: www.arcutis.com

Address:

3027 Townsgate Road, Suite 300, Westlake Village, United States

ZManicItalian Aug. 7 at 4:25 PM

$ARQT Canada sales started in April. Thinking those start ramping up soon. I searched the call transcript for "Canada", but doesn't seem like the topic was discussed

0 · Reply

ggrail Aug. 7 at 4:05 PM

$ARQT This beatdown is overblown. Lots of big money is beating down the price. They had a good quarter but mentioned in the call that Q3 is a generally slower quarter. The company doesn't seem to care about fluctuations or shareholders. Zoryve is establishing itself as the go-to non-steroidal. The approval for new indications is a boon they will seize upon. Atopic dermatitis in kids and babies will be what makes this a profitable company in early 2026. But need to control SG&A and need a new drug, not just new indications.

0 · Reply

ZManicItalian Aug. 7 at 3:49 PM

$ARQT red to green, red to green

0 · Reply

Forget1t Aug. 7 at 3:04 PM

$ARQT Dont be fooled The are robbing your shares

0 · Reply

APSinvest10 Aug. 7 at 2:48 PM

$ARQT now we know why CSO lead the sell off of ARQT shares, it is all due to the termination of 255 program.

1 · Reply

zawojak Aug. 7 at 2:37 PM

$ARQT just bought plenty of $CCCC

0 · Reply

zawojak Aug. 7 at 2:33 PM

$ARQT buy, you won't regret in a month time

0 · Reply

Franciscomaligno Aug. 7 at 2:30 PM

$ARQT completely agree, and which is the best time to generate panic? DAY AFTER EARNINGS OF COURSE !!! DON'T SELL TO THOSE MF !!!

0 · Reply

JazzyJ03 Aug. 7 at 2:30 PM

$ARQT

0 · Reply

ZManicItalian Aug. 7 at 2:30 PM

$ARQT loading 2026calls 🤑✌️

0 · Reply

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:00 PM EDT - 20 hours ago

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 1, 2025, 3:54 PM EDT - 5 days ago

Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion

Jul 23, 2025, 4:00 PM EDT - 14 days ago

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Jul 3, 2025, 4:00 PM EDT - 4 weeks ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 27, 2025, 11:25 PM EDT - 5 weeks ago

Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction

Jun 26, 2025, 8:00 AM EDT - 6 weeks ago

Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Jun 25, 2025, 4:43 AM EDT - 6 weeks ago

Arcutis Biotherapeutics: Another Approval Under Their Belt

Jun 12, 2025, 11:57 PM EDT - 7 weeks ago

Arcutis: Out Of The Woods, Ready For Commercialization

Jun 10, 2025, 8:00 AM EDT - 2 months ago

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Jun 6, 2025, 8:00 AM EDT - 2 months ago

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

Jun 5, 2025, 1:07 AM EDT - 2 months ago

Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside

May 29, 2025, 4:00 PM EDT - 2 months ago

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 22, 2025, 2:12 PM EDT - 2 months ago

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

May 15, 2025, 9:29 AM EDT - 3 months ago

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

May 7, 2025, 11:18 AM EDT - 3 months ago

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

May 6, 2025, 11:00 PM EDT - 3 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:00 PM EDT - 3 months ago

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 19, 2025, 1:41 AM EDT - 3 months ago

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Apr 17, 2025, 8:00 AM EDT - 4 months ago

Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Apr 10, 2025, 4:30 PM EDT - 4 months ago

Arcutis Announces Chief Financial Officer Transition

Apr 2, 2025, 1:16 PM EDT - 4 months ago

Arcutis and Padagis Agree to Stay Patent Lawsuit

Mar 27, 2025, 8:00 AM EDT - 4 months ago

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 8:16 AM EDT - 4 months ago

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

TNXP

Mar 7, 2025, 8:00 AM EST - 5 months ago

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Feb 28, 2025, 9:00 AM EST - 5 months ago

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Feb 27, 2025, 6:17 AM EST - 5 months ago

Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck

Feb 26, 2025, 2:28 PM EST - 5 months ago

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

Feb 26, 2025, 8:00 AM EST - 5 months ago

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Feb 25, 2025, 10:53 PM EST - 5 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:00 PM EST - 5 months ago

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 5 months ago

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

Feb 18, 2025, 4:35 PM EST - 6 months ago

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

Feb 4, 2025, 9:15 AM EST - 6 months ago

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a "Clear Win for Your Skin"

Jan 12, 2025, 8:30 AM EST - 7 months ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Nov 15, 2024, 8:30 AM EST - 9 months ago

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 7, 2024, 2:24 AM EST - 9 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:00 PM EST - 9 months ago

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Oct 23, 2024, 4:00 PM EDT - 10 months ago

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Oct 22, 2024, 7:36 AM EDT - 10 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

OGN TMDX

Oct 18, 2024, 8:20 AM EDT - 10 months ago

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Sep 25, 2024, 1:00 AM EDT - 11 months ago

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

Sep 24, 2024, 8:00 AM EDT - 11 months ago

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Aug 22, 2024, 5:13 PM EDT - 1 year ago

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 15, 2024, 12:43 AM EDT - 1 year ago

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 9:00 PM EDT - 1 year ago

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 4:00 PM EDT - 1 year ago

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 29, 2024, 7:35 AM EDT - 1 year ago

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

Jul 29, 2024, 7:30 AM EDT - 1 year ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

ZManicItalian Aug. 7 at 4:25 PM

$ARQT Canada sales started in April. Thinking those start ramping up soon. I searched the call transcript for "Canada", but doesn't seem like the topic was discussed

0 · Reply

ggrail Aug. 7 at 4:05 PM

0 · Reply

ZManicItalian Aug. 7 at 3:49 PM

$ARQT red to green, red to green

0 · Reply

Forget1t Aug. 7 at 3:04 PM

$ARQT Dont be fooled The are robbing your shares

0 · Reply

APSinvest10 Aug. 7 at 2:48 PM

$ARQT now we know why CSO lead the sell off of ARQT shares, it is all due to the termination of 255 program.

1 · Reply

zawojak Aug. 7 at 2:37 PM

$ARQT just bought plenty of $CCCC

0 · Reply

zawojak Aug. 7 at 2:33 PM

$ARQT buy, you won't regret in a month time

0 · Reply

Franciscomaligno Aug. 7 at 2:30 PM

$ARQT completely agree, and which is the best time to generate panic? DAY AFTER EARNINGS OF COURSE !!! DON'T SELL TO THOSE MF !!!

0 · Reply

JazzyJ03 Aug. 7 at 2:30 PM

$ARQT

0 · Reply

ZManicItalian Aug. 7 at 2:30 PM

$ARQT loading 2026calls 🤑✌️

0 · Reply

JazzyJ03 Aug. 7 at 2:29 PM

$ARQT

0 · Reply

HR4480 Aug. 7 at 2:23 PM

$ARQT Give me low 13's and I'll buy back in

0 · Reply

5xStarTrader Aug. 7 at 2:12 PM

$ARQT Market Makers are flaunting their insuperable powers to manipulate any share price at any given time, under any market conditions, or positive earnings circumstance…at their sole discretion…to deliver their Max-Pain-Point OpEx Price Point on the 3rd Friday of the month, in order to make the most investors lose the most money possible…again.

0 · Reply

DonCorleone77 Aug. 7 at 2:02 PM

$ARQT TD Cowen raises price target on Arcutis Biotherapeutics to $25 from $20 -- Keeps 'Buy' rating.

1 · Reply

Hottehueh Aug. 7 at 2:00 PM

$ARQT loaded!

0 · Reply

FetchDog Aug. 7 at 2:00 PM

$ARQT Bought a bunch on the drop.

0 · Reply

mememtus Aug. 7 at 1:50 PM

$ARQT buying more ☺️

0 · Reply

Bornjever Aug. 7 at 1:48 PM

$ARQT yes a stop loss raid as Charlie always said to know what you hold and the thieves come in at night to steal. If I am holding a company I should not sell unless there are facts to back it up but some folks believe in stop losses more than anything.

0 · Reply

khanso Aug. 7 at 1:47 PM

$ARQT this is a shorty raid…hang in there for a few days

0 · Reply

AdiDasRom Aug. 7 at 1:46 PM

$ARQT Don't be fooled, it's classic here, it'll be back.

0 · Reply

TheGunnerAB Aug. 7 at 1:44 PM

$ARQT imagine if they missed. Crazy!

0 · Reply

Rhody27 Aug. 7 at 1:40 PM

$ARQT the reason this is tanking is?

0 · Reply

Market Cap	1.83B
Revenue (ttm)	196.54M
Net Income (ttm)	-140.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-71.25%
Debt to Equity Ratio	0.75

Volume	1,918,600
Avg Vol	1,760,740
Day's Range	N/A - N/A
Shares Out	119.20M
Stochastic %K	96%
Beta	1.84
Analysts	Strong Sell
Price Target	$21.25